Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study
| Autor: | Liu, B, Beral, V, Balkwill, A, Green, J, Sweetland, S, Reeves, G, Collaborators, MWS |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Million Women Study
medicine.medical_specialty Hormone Replacement Therapy medicine.medical_treatment Gallbladder disease Administration Oral Gallbladder Diseases Administration Cutaneous Cohort Studies 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Prospective Studies 030212 general & internal medicine Prospective cohort study General Environmental Science Gynecology 030219 obstetrics & reproductive medicine business.industry Research Gallbladder General Engineering Hormone replacement therapy (menopause) General Medicine Middle Aged medicine.disease 3. Good health Hospitalization Postmenopause medicine.anatomical_structure England Scotland General Earth and Planetary Sciences Female Cholecystectomy Hormone therapy business Cohort study |
| Zdroj: | The BMJ |
| DOI: | 10.1136/bmj.a386 |
| Popis: | Objective: To determine whether transdermal compared with oral use of hormone replacement therapy reduces the risk of gallbladder disease in postmenopausal women. Design: Prospective cohort study (Million Women Study). Setting: Women registered with the National Health Service (NHS) in England and Scotland. Participants: 1 001 391 postmenopausal women (mean age 56) recruited between 1996 and 2001 from NHS breast screening centres and followed by record linkage to routinely collected NHS hospital admission data for gallbladder disease. Main outcome measures: Adjusted relative risk and standardised incidence rates of hospital admission for gallbladder disease or cholecystectomy according to use of hormone replacement therapy. Results: During follow-up 19 889 women were admitted for gallbladder disease; 17 190 (86%) had a cholecystectomy. Compared with never users of hormone replacement therapy, current users were more likely to be admitted for gallbladder disease (relative risk 1.64, 95% confidence interval 1.58 to 1.69) but risks were substantially lower with transdermal therapy than with oral therapy (relative risk 1.17, 1.10 to 1.24 v 1.74, 1.68 to 1.80; heterogeneity P0.625 mg, 1.91 (1.78 to 2.04) v ≤0.625 mg, 1.76 (1.68 to 1.84); heterogeneity P=0.02; estradiol >1 mg, 1.68 (1.59 to 1.77) v |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|